Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03332498 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03332498 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 40 participants.
The verdict
NCT03332498, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) (or the highest protocol-defined dose level in the absence of establishing an MTD) of ibrutinib in combination with pembrolizumab in participants with advanced, refractory colorectal cancers.
Interventions
- DRUG Pembrolizumab
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2021-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03332498
The ClinicalTrials.gov registry entry for NCT03332498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03332498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03332498 about?
NCT03332498 is a clinical study titled "Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers". The purpose of this study is to determine the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) (or the highest protocol-defined dose level in the absence of establishing an MTD) of ibrutinib in combination with pembrolizumab in par...
What is the current status of trial NCT03332498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-01-24. Estimated completion is 2021-09-09.
What interventions are being tested in trial NCT03332498?
The interventions under investigation include: Pembrolizumab (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03332498?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.